Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis

Sponsor
Novartis Pharmaceuticals
Study ID
NCT05650060
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Secukinumab — DRUG
    all patients with psoriasis who received secukinumab

Study Details

This study was a non-interventional, retrospective study collecting data from hospital medical records. Approximately 200 adult patients with moderate to severe plaque psoriasis who were treated with secukinumab from hospitals in Thailand that participated in this study were expected for data collection.

Key Dates

Start date
Jan 20, 2021
Status verified
Apr 2023
Primary completion
Dec 23, 2021
Completion
Dec 23, 2021

Study Design

Enrollment
163 participants (actual)

Arms

  • Arm: Secukinumab
    all patients with psoriasis who received secukinumab

Primary Outcome Measure

Age [ Time Frame: Baseline ]

Related Studies